@article{34d08f4d6bf64d2fb4966afd1ff4d933,
title = "Migraine headache is present in the aura phase: A prospective study",
abstract = "Objectives: Migraine aura is commonly considered to be a distinct phase of a migraine attack that precedes headache. The objective of the study was to examine a large number of prospectively recorded attacks of migraine with aura and determine the timing of headache and other migraine symptoms relative to aura. Methods: As part of a clinical trial we collected prospective data on the time course of headache and other symptoms relative to the aura. Patients (n = 267) were enrolled from 16 centers, and asked to keep a headache diary for 1 month (phase I). They were asked to record headache symptoms as soon as possible after aura began and always within 1 hour of aura onset. A total of 456 attacks were reported during phase I by 201 patients. These patients were then randomized and included in phase II, during which a total of 405 attacks were reported in 164 patients. In total, we present data from 861 attacks of migraine with aura from 201 patients. Results: During the aura phase, the majority of attacks (73%) were associated with headache. Other migraine symptoms were also frequently reported during the aura: nausea (51%), photophobia (88%), and photophobia (73%). During the first 15 minutes within the onset of aura, 54% of patients reported headache fulfilling the criteria for migraine. Conclusion: Our results indicate that headaches as well as associated migraine symptoms are present early, during the aura phase of the migraine attack in the majority of patients.",
author = "Hansen, {Jakob M.} and Lipton, {Richard B.} and Dodick, {David W.} and Silberstein, {Stephen D.} and Saper, {Joel R.} and Aurora, {Sheena K.} and Goadsby, {Peter J.} and Andrew Charles",
note = "Funding Information: Study funding: Supported by grants from the International Headache Society, The Lundbeck Foundation, The Foundation of Ulla, Mogens Folmer Andersen, and “L{\ae}gernes Forsikringsforening af 1891.” Funding Information: J. M{\o}ller Hansen reports no disclosures. R.B. Lipton receives research support from the NIH, the National Headache Foundation, and the Migraine Research Fund; serves on the editorial board of Neurology{\textregistered}; holds stock options in eNeura Therapeutics (a company without commercial products); and serves as consultant, advisory board member, or has received honoraria from Allergan, American Headache Society, Autonomic Technologies, Boston Scientific, Bristol Myers Squibb, Cognimed, Colucid, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, MAP, Merck, Nautilus Neuroscience, Novartis, NuPathe, Pfizer, and Vedanta. D.W. Dodick has within the past 4 years served on advisory boards, has consulted for, and received travel reimbursement from Allergan, Alder, Pfizer, Merck, Coherex, Ferring, Neurocore, Neuralieve, Neuraxon, NuPathe Inc., MAP, SmithKlineBeecham, Boston Scientific, Medtronic, Inc., Nautilus, Eli Lilly & Company, Novartis, Colucid, GlaxoSmithKline, Autonomic Technologies Inc., MAP Pharmaceuticals, Inc., Zogenix, Inc., Impax Laboratories, Inc., Bristol Myers Squibb, Nevro Corporation, and Arteaus. Within the past 4 years, Dr. David W. Dodick has received funding for travel, speaking, or editorial activities from CogniMed, Scientiae, Intramed, SAGE Publishing, Lippincott Williams & Wilkins, Oxford University Press, Cambridge University Press, Miller Medical, and Annenberg for Health Sciences. Within the past 3 years, Dr. David W. Dodick has received research grant support from Advanced Neurostimulation Systems, Boston Scientific, St Jude Medical, Inc., Medtronic, National Institute of Neurological Disorders and Stroke/NIH, and Mayo Clinic. S.D. Silberstein served on advisory boards or has consulted for Allergan, Alder, Amgen, AGA Pfizer, Merck, Coherex, Neuralieve, Boston Scientific, Medtronic, Inc., Nautilus, Eli Lilly & Company, Novartis, Colucid, GlaxoSmithKline, Autonomic Technologies Inc., MAP Pharmaceuticals, Inc., and Zogenix, Inc. Within the past 4 years, he has received funding for travel, speaking, or editorial activities from CogniMed, Scientiae, Intramed, Oxford University Press, and Cambridge University Press. Within the past 3 years, he has received research grant support from Advanced Neurostimulation Systems, AGA, Boston Scientific, Capnia, St Jude Medical, Inc., MAP, Medtronic, National Institute of Neurological Disorders and Stroke/NIH, Nu Pathe Merck, GSK, and Eli Lilly. J.R. Saper is a consultant, advisory board member, or both for Allergan, Ortho-McNeil, Medtronic, Neuralieve, ANS, Pozen (also stock), and GlaxoSmithKline; has received research grants from GlaxoSmithKline, Merck, Allergan, Cypress, Eli Lilly, ANS, MAP Pharma, Capnia, Depomed, XLT, Schwartz, and NuPathe; and receives honoraria from GlaxoSmithKline, Merck, Ortho-McNeil, and Purdue Pharma. S.K. Aurora received grant and research support from Advanced Bionics, Alexza, Allergan, GlaxoSmithKline, MAP Pharmaceuticals, Merck, Ortho-McNeil, Neuralieve, and Takeda; has served as a consultant for Ortho-McNeil Pharmaceutical, Merck, GlaxoSmithKline, Allergan, and Neuralieve; and has received honoraria from Merck, GlaxoSmithKline, NuPathe, and Ortho-McNeil Pharmaceutical. P.J. Goadsby reports having received research grants from Boston Scientific, Medtronic, GSK, MSD, MAP, Johnson & Johnson, and eNeura, and consulting fees or honoraria from Allergan, Almirall, ATI, BMS, Boehringer, Boston Scientific, Coherex, Colucid, Lilly, Medtronic, Minster, MSD, MAP, eNeura, NeurAxon, NTP, and Pfizer. A. Charles is an advisory board consultant for AGA Medical, Bristol Myers Squibb, eNeura, MAP Pharmaceuticals, Merck, and Monosol Rx. He has received research grant support from MAP Pharmaceuticals. Go to Neurology.org for full disclosures. ",
year = "2012",
month = nov,
day = "13",
doi = "10.1212/WNL.0b013e3182749eed",
language = "English (US)",
volume = "79",
pages = "2044--2049",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "20",
}